First-line highly active antiretroviral therapy regimen:safety and tolerance

( views:, downloads: )
Author:
CHEN Jun(Division of Infectious Diseases,Public Health Clinieal Center Affiliated to Fudan University,Shanghai 201508,China)
ZHANG Renfang(Division of Infectious Diseases,Public Health Clinieal Center Affiliated to Fudan University,Shanghai 201508,China)
ZHENG Yu-fang(Division of Infectious Diseases,Public Health Clinieal Center Affiliated to Fudan University,Shanghai 201508,China)
LIU Li(Division of Infectious Diseases,Public Health Clinieal Center Affiliated to Fudan University,Shanghai 201508,China)
PAN Cheng-en(Division of Infectious Diseases,Public Health Clinieal Center Affiliated to Fudan University,Shanghai 201508,China)
LU Hong-zhou(Division of Infectious Diseases,Public Health Clinieal Center Affiliated to Fudan University,Shanghai 201508,China)
Journal Title:
CHINESE JOURNAL OF CLINICAL INFECTIOUS DISEASES
Issue:
Volume 2, Issue 03, 2009
DOI:
10.3760/cma.j.issn.1674-2397.2009.03.003
Key Word:
Acquired immunodeficieney syndrome;Highly active antiretroviral therapy;Safety;Tolerance

Abstract: Objective To evaluate the safety and tolerance of the first-line hiighly active antiretroviral therapy(HAART)regimen in Chinese HIV/AIDS patients.Methods The clinical data and laboratory results were retrospectively reviewed in 95 HIV/AIDS outpatients receiving first-line HAART regimen of zidovudine,lamivudine and efavirenz(or nevirapine)in Public Heahh Clinical Center Affiliated to Fudan University during January 2005 and August 2008.Mixed effects model and X2 test or Fisher test were used to analyze panel data and ratio data respectively.Results Totally 81%(77/95)patients had adverse events in the course of treatment,11.6%(11/95)developed grade 3 or higher adverse effects.Hematological adverse events and hepatotoxity were the most common in term of laboratory events with the total incidence of 46.3%(44/95)and 27.4%(26/95)respectively;8.4%(8/95)and 6.3%(6/95)were grade 3 or higher.In clinical events,30.5%(29/95),37.8%(36/95)and 27.4%(26/95)patients had dermatological,gastrointestinal and neurological adverse events respectively,however,only 1.1%(1/95)experienced grade 3 or higher dermatological adverse events.Conclusion The first line HAART regimen is safe and well tolerated in Chinese HIV/AIDS patients.

  • [1]World Health Organization.Sealing up antiretroviral therapy in resource-limited settings:treatment guidelines for a public health approach,2003 revision[S/OL].Geneva:World Health Organization,2004[2009-4-30].http://www.who.int/hiv/pub/prev_care/en/arvrevision2003 en.pdf.
  • [2]World Health Organization.Antiretreviral therapy for HIV infection in adults and adolescents in resource-limited settings:towards universal access.Recommendations for a Public Health Approach (2006 revision).Geneva:World Health Organization,2006[2009-4-30].http://www.who.iut/hiv/pub/guidelines/adult/en/index.html.
  • [3]Zhang FJ.National manual of free AIDS antiretrovind therapy.Beijing:People's Medical Publishing House,2007:6.(in Chinese)张福杰.国家免费艾滋病抗病毒药物治疗手册.北京:人民卫生出版社,2007:6.
  • [4]AIDS Clinical Trials Group.Division of AIDS table for grading the severity of adult and pediatric adverse events[S/OL].2004[2009-4-30].http://www3.niaid.nih.gov/LabsAnd Resonrces/resonrces/DAIDSClinPsrch/PDF/DAIDSAEGradingTable.pdf.
  • [5]Hoffmann CJ,Fielding KL,Charalambous S,et al.Antiretroviral therapy using zidovudine,lamivudine,and efavirenz in South Africa:tolerability and clinical events.AIDS,2008,22(1):67-74.
  • [6]Lochet P,Peyriere H,Lotthe A,et al.Long-term assessment of neuropsychiatric adverse reactions associated with efavirens.HIV Mad,2003,4(1):62-66.
  • [7]Clifford DB,Evans S,Yang Y,et al.Impact of efavirenz on neuropsychoiogical perfonnsnce and symptoms in HIV-infected individuals.Ann Intern Med,2005,143(10):714-721.
  • [8]Berhane K,Karim R,Cohan MH,et al.Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women:Women's Interagoncy HIV Study.J Acquir Immune Defic Syndr,2004,37(2):1245-1252.
  • [9]Moyle G,Sawyer W,Law M,et al.Changes in hematologic parameters and efficacy of thymidine analogue-based,highly active antiretroviral therapy:a meta-analysis of six prospective,randomized,comparative studies.Clin Ther,2004,26(1):92-97.
  • [10]Lovine AM,Karim R,Mack W,et al.Neutropenia in human immunodeficieney virus infection:data from the women's interagency HIV study.Arch Intern Mad,2006,166 (4):405-410.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn